[go: up one dir, main page]

MX2007007602A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.

Info

Publication number
MX2007007602A
MX2007007602A MX2007007602A MX2007007602A MX2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A MX 2007007602 A MX2007007602 A MX 2007007602A
Authority
MX
Mexico
Prior art keywords
glp
methods
mimetibody
agonist
specified portion
Prior art date
Application number
MX2007007602A
Other languages
English (en)
Inventor
Kristen Picha
Karyn T O'neil
John O'neil
Gang Xu
Michael Lark
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MX2007007602A publication Critical patent/MX2007007602A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invencion se relaciona con al menos un mimeticuerpo o agonista o una porcion o variante especificada de GLP-1 humano, novedoso, que incluye acidos nucleicos aislados que codifican al menos un mimeticuerpo o agonista o porcion o variantes especificadas de GLP-1, mimeticuerpo o agonista o una porcion o variantes especificadas de GLP-1, mimeticuerpo o agonista o una porcion o variantes especificadas de GLP-1, vectores, celulas transgenicas, animales o plantas transgenicos y metodos para hacer y utilizar los mismos, incluyendo composiciones, metodos y dispositivo terapeuticos y/o de diagnostico relacionados con la diabetes.
MX2007007602A 2004-12-22 2005-12-22 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. MX2007007602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63831304P 2004-12-22 2004-12-22
PCT/US2005/046602 WO2007046834A2 (en) 2004-12-22 2005-12-22 Glp-1 agonists, compositions, methods and uses

Publications (1)

Publication Number Publication Date
MX2007007602A true MX2007007602A (es) 2007-12-07

Family

ID=37962937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007602A MX2007007602A (es) 2004-12-22 2005-12-22 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.

Country Status (17)

Country Link
US (1) US20070128193A1 (es)
EP (1) EP1843788A4 (es)
JP (1) JP2008525477A (es)
KR (1) KR20070090036A (es)
CN (1) CN101415439A (es)
AU (1) AU2005337493A1 (es)
BR (1) BRPI0519241A2 (es)
CA (1) CA2592065A1 (es)
CR (1) CR9266A (es)
EA (1) EA200701362A1 (es)
IL (1) IL183940A0 (es)
MX (1) MX2007007602A (es)
NI (1) NI200700158A (es)
NO (1) NO20073814L (es)
SG (1) SG158158A1 (es)
WO (1) WO2007046834A2 (es)
ZA (1) ZA200706030B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
KR101486829B1 (ko) 2005-09-14 2015-01-29 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
WO2007081654A2 (en) * 2005-12-28 2007-07-19 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
SI2373681T1 (sl) 2008-12-10 2017-05-31 Glaxosmithkline Llc Corporation Service Company Farmacevtski sestavki albiglutida
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US20140045754A1 (en) * 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9950038B2 (en) * 2011-08-05 2018-04-24 The Trustees Of The Universiy Of Pennsylvania Methods and compositions for inhibiting delayed graft function
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
JP2015508812A (ja) * 2012-03-01 2015-03-23 イエダ リサーチ アンド ディベロプメント カンパニー リミテッド 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10988737B2 (en) * 2015-04-28 2021-04-27 Universite De Strasbourg Clinical gene signature-based human cell culture model and uses thereof
CN105504026B (zh) * 2015-12-24 2018-12-07 广东医科大学 一种pac1-r和glp-1r的双向激动剂ot23及应用
EP3470424B1 (en) * 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
AU2021285138A1 (en) 2020-06-03 2023-02-02 Københavns Universitet GLP1R agonist NMDAR antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP1355942B1 (en) * 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
KR20050033563A (ko) * 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2007046834A2 (en) 2007-04-26
WO2007046834A3 (en) 2009-06-18
IL183940A0 (en) 2007-10-31
BRPI0519241A2 (pt) 2009-01-06
NO20073814L (no) 2007-09-14
EP1843788A2 (en) 2007-10-17
AU2005337493A1 (en) 2007-04-26
NI200700158A (es) 2008-05-13
EA200701362A1 (ru) 2008-08-29
CN101415439A (zh) 2009-04-22
JP2008525477A (ja) 2008-07-17
CR9266A (es) 2008-09-09
US20070128193A1 (en) 2007-06-07
EP1843788A4 (en) 2009-11-18
KR20070090036A (ko) 2007-09-04
SG158158A1 (en) 2010-01-29
ZA200706030B (en) 2009-12-30
CA2592065A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
TW200602491A (en) Human GLP-1 mimetibodies, compositions, methods and uses
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
MX2009006892A (es) Uso de agonistas del receptor de peptido similar al glucagon de tipo 1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles de lipidos.
MX2009005901A (es) Nuevos polipeptidos cristalinos de bacillus thuringiensis, polinucleotidos y composiciones de los mismos.
TW200626173A (en) IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
MA29088B1 (fr) Composes d'indazole-carboxamide.
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
TW200716174A (en) Anti-MCP-1 antibodies, compositions, methods and uses
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
MX2007011975A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos.
DK1476012T3 (da) Transgene mus, der udtrykker PRKAG3
TW200600511A (en) Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylamino]-phenyl}-amide
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal